How long does Mounjaro take to start working?

What the SURMOUNT-1 trial says about when results appear

The clearest evidence comes from SURMOUNT-1, a 72-week randomised trial of tirzepatide in adults with obesity but without type 2 diabetes, published in the New England Journal of Medicine. Participants at the 15 mg dose lost an average of around 20–21% of body weight by the end of the study. What the headline figure does not tell you is the shape of that curve.

In the trial, measurable weight loss began in the first four weeks. It was modest (often 2–3% of starting weight) but consistent. The rate of loss then steepened as doses increased and participants settled into treatment. By around twelve weeks, many had lost enough to notice visible changes. The bulk of the total loss came between weeks twelve and fifty-two, which lines up with the dose-escalation schedule: the body responds more strongly as tirzepatide reaches its therapeutic range.

The NHS medicines information for tirzepatide echoes this pattern, noting that treatment is titrated over time and that individual responses vary. If you want a fuller picture of how fast Mounjaro starts working, including what the early timeline looks like week by week, our dedicated page walks through what to expect at each stage. Comparing your week-four result against the trial's week-72 average is a fast route to unnecessary discouragement.

The first four weeks: what 2.5 mg actually does

The starting dose of 2.5 mg is not a therapeutic dose in the usual sense. Its job is adjustment, reducing the nausea, stomach discomfort, and other gastrointestinal effects that can accompany a GLP-1 or dual-agonist medicine introduced too quickly. Some people do lose weight at 2.5 mg; others see very little change on the scales and feel mildly nauseous. Both are normal.

What most people do notice during the first pen is a shift in appetite. Meals that used to feel routine suddenly feel like enough at two-thirds of the plate. The urge to graze between meals quietens. These early signals matter (they confirm the medicine is active) even when the number on the scales is barely moving.

Timing here is practical, too. If your first pen arrives on a Thursday, your four-week review lands around a Friday, which may or may not suit a busy schedule. A question our prescribers hear regularly is whether a dose increase can wait a few extra days, for a holiday, a payday, a child's school half-term. In most cases a short delay makes no clinical difference; your prescriber is the right person to confirm that.

For a detailed look at the early-weeks experience, the first-injection timeline page covers what to expect hour by hour in those initial days.

Weeks four to twenty-four: the dose-escalation phase

From 2.5 mg, most people step up every four weeks, to 5 mg, then 7.5 mg, and so on, up to a maximum of 15 mg. The prescriber decides each step based on how the current dose is tolerated and what progress looks like. This is the phase where weight loss accelerates for most people.

By week twelve, the average person in SURMOUNT-1 had lost around 8–10% of their starting weight at the higher doses. By week twenty-four, many had reached 15% or more. Those figures are trial averages, not guarantees, and they include people who responded strongly and people who responded modestly.

Side effects tend to be most pronounced in this phase, usually peaking in the week after a dose increase before settling. Nausea is the most commonly reported; it typically eases within a few days. Our page on how quickly Mounjaro starts to work goes into more detail on the physiological mechanisms behind the appetite changes during this window.

If you are thinking about what private treatment costs during this phase, the Mounjaro pricing page sets out the cost context honestly, including what an all-in price from a regulated pharmacy should cover.

Beyond six months: maintenance and what long-term looks like

Once a stable maintenance dose is reached (the highest dose that is effective and well-tolerated) weight loss continues but typically at a slower pace than during escalation. This is not a plateau in the clinical sense; it is the medicine doing its job at steady state. The body adjusts, and the rate of loss moderates.

The SURMOUNT-1 72-week endpoint represents roughly 18 months of treatment. People who reached 15 mg and stayed on it saw the greatest absolute losses. Those on lower maintenance doses still saw meaningful reductions, just smaller ones on average. NICE's appraisal of tirzepatide (published as NICE TA1026) notes that if weight loss is less than 5% after six months at the highest tolerated dose, continuing is reviewed. That threshold is a clinical checkpoint, not a verdict; it is one of several data points a prescriber weighs.

Weight loss medicines work best alongside consistent dietary changes and activity, and that combination is what sustains results long-term. If you want to understand how the wider treatment landscape compares, the weight-loss treatment overview covers the options currently available in the UK.

Every repeat prescription at nume is clinically re-reviewed before dispatch. There are no auto-renewals. If your progress, dose, or circumstances change, that review is the moment to raise it. You can browse common questions beforehand, or reach our team directly if something specific comes up between reviews.

If you are ready to find out whether tirzepatide is clinically suitable for you, the next step is straightforward. Speak to our prescribers through a free consultation, reviewed the same day by a real clinician.